With Bayer's new launches in infancy, Eylea and Xarelto still rule its pharma business—but for how long?

Bayer is gradually shifting its pharma focus to a group of new blockbuster candidates and novel platforms. But before those drugs realize their potential, eye med Eylea and blood thinner Xarelto remain the pillars.